Penumbra, Inc. Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) reported Q2 2024 financial results with revenue of $299.4 million, up 14.5% year-over-year. U.S. thrombectomy revenue increased 24.9% to $153.7 million. The company reported a loss from operations of $81.0 million, including $110.3 million in one-time non-cash impairment charges. Excluding these charges, non-GAAP income from operations was $31.7 million.

Penumbra updated its 2024 revenue guidance to $1,180-$1,200 million, a $60 million reduction at the midpoint. This change reflects challenges in China, delays in European product launches, strategic changes in Immersive Healthcare, and adjusted U.S. thrombectomy growth expectations. The company maintains its outlook for non-GAAP gross margin and operating margin expansion.

Positive

• Revenue increased 14.5% year-over-year to $299.4 million
• U.S. thrombectomy revenue grew 24.9% to $153.7 million
• Non-GAAP income from operations improved to $31.7 million from $20.3 million in Q2 2023
• Cash and marketable investments increased by $26.2 million in Q2 2024

Negative

• Reported loss from operations of $81.0 million due to impairment charges
• Revenue guidance for 2024 reduced by $60 million at the midpoint
• Challenges in China market and delays in European product launches
• Global embolization and access products revenue declined 3.1%

Financial Analyst

Penumbra's Q2 2024 results present a mixed picture. The company reported revenue growth of 14.5% year-over-year, reaching $299.4 million. This growth was primarily driven by strong performance in the U.S. thrombectomy segment, which saw a 24.9% increase. However, the company faced challenges in other areas.

The most significant development is the $110.3 million one-time non-cash impairment and inventory write-down related to Immersive Healthcare assets. This resulted in a loss from operations of $81.0 million, compared to an income of $17.9 million in Q2 2023. Excluding these charges, non-GAAP income from operations was $31.7 million, showing underlying profitability.

The company's updated guidance for 2024 is concerning. Penumbra reduced its full-year revenue forecast by $60 million at the midpoint, citing challenges in China, delays in European product launches and a strategic shift away from Immersive Healthcare. The revised U.S. thrombectomy growth projection of 23-25% for 2024, while still strong, indicates a slight slowdown.

On a positive note, Penumbra's cash position improved by $26.2 million in Q2, driven by increased non-GAAP profitability and working capital improvements. The company also expects non-GAAP gross margin and operating margin expansion for the full year, which could help offset some of the revenue challenges.

Investors should closely monitor Penumbra's ability to navigate the challenges in China and Europe, as well as the execution of its U.S. thrombectomy strategy in the coming quarters.

Medical Device Industry Expert

Penumbra's Q2 results highlight both the strengths and vulnerabilities in the medical device sector. The company's thrombectomy segment, particularly in the U.S., continues to be a strong growth driver. The 24.9% increase in U.S. thrombectomy revenue suggests ongoing market expansion and potentially increased adoption of Penumbra's technologies in stroke treatment.

However, the challenges in the embolization and access products segment, especially internationally, are noteworthy. The 3.1% decline in this segment, driven by a 10.8% decrease in international sales, could indicate increased competition or market saturation in certain regions.

The $110.3 million impairment related to Immersive Healthcare assets is a significant development. This suggests a strategic pivot away from virtual reality applications in healthcare, which had been seen as a potential growth area for medical device companies. It's important to understand whether this is a Penumbra-specific issue or indicative of broader challenges in the immersive healthcare space.

The revised guidance, particularly the $20 million reduction due to challenges in China, aligns with broader industry trends. Many medical device companies are facing headwinds in the Chinese market due to economic pressures and potential shifts in healthcare policies. This situation warrants close attention as China has been a key growth market for the industry.

The slight delay in European product launches (FLASH and BOLT 7 CAVT) highlights the ongoing regulatory complexities in bringing new medical devices to market, especially in different geographical regions. This is a common challenge in the industry and can impact short-term growth projections.

Overall, while Penumbra faces some headwinds, its core thrombectomy business remains strong. The company's ability to maintain gross margin expansion despite these challenges is commendable and speaks to its operational efficiency.

ALAMEDA, Calif., July 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2024.

• Revenue of $299.4 million in the second quarter of 2024, an increase of 14.5% or 14.7% in constant currency¹, compared to the second quarter of 2023.
  
  
• U.S. thrombectomy revenue of $153.7 million in the second quarter of 2024 increased 24.9% compared to the second quarter of 2023.
  
  
• Loss from operations of $81.0 million, which includes $110.3 million of one-time non-cash impairment and inventory write-down charges related to its Immersive Healthcare assets, and non-GAAP income from operations¹ of $31.7 million in the second quarter of 2024.
  
  
• Adjusted EBITDA¹ of $46.3 million or adjusted EBITDA margin of 15.5% in the second quarter of 2024.
  
  
• Cash and marketable investments increased $26.2 million in the second quarter of 2024 compared to the first quarter of 2024 driven by an increase in non-GAAP profitability and improvements in working capital.

Second Quarter 2024 Financial Results
Total revenue increased to $299.4 million for the second quarter of 2024 compared to $261.5 million for the second quarter of 2023, an increase of 14.5%, or 14.7% in constant currency¹. The United States represented 72.9% of total revenue and international represented 27.1% of total revenue for the second quarter of 2024. Revenue from the U.S. increased 16.8% while revenue from our international regions increased 8.7%, or 9.4% in constant currency¹. Revenue from sales of our global thrombectomy products grew to $203.5 million in the second quarter of 2024, an increase of 25.2%, or 25.4% in constant currency¹ over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 24.9% over the same period a year ago. Revenue from sales of our global embolization and access products declined to $95.9 million for the second quarter of 2024, a decrease of 3.1%, or 3.0% in constant currency¹ from the same period a year ago, driven primarily by our international embolization and access products which decreased by 10.8% from the same period a year ago.

Gross profit for the second quarter of 2024 was $162.8 million, or 54.4% of total revenue, including a $33.4 million inventory impairment charge to cost of revenue in connection with an inventory write-down due to the impairment of assets related to our immersive healthcare business. Excluding this charge, non-GAAP gross profit¹ was $196.2 million, or 65.5% of total revenue for the second quarter of 2024, compared to GAAP and non-GAAP gross profit of $166.9 million, or 63.8% of total revenue for the second quarter of 2023. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.

Total operating expenses, including a $2.4 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition for both periods and a $76.9 million long-lived assets impairment charge associated with the impairment of assets related to our immersive healthcare business during the second quarter of 2024, were $243.8 million, or 81.4% of total revenue for the second quarter of 2024, and $149.0 million, or 57.0% of total revenue for the second quarter of 2023. Excluding the charges noted above, total non-GAAP operating expenses¹ were $164.5 million, or 54.9% of total revenue, for the second quarter of 2024, and $146.6 million, or 56.1% of total revenue for the second quarter of 2023. R&D expenses were $24.9 million for the second quarter of 2024, compared to $21.5 million for the second quarter of 2023. SG&A expenses were $141.9 million for the second quarter of 2024, compared to $127.4 million for the second quarter of 2023.

Loss from operations was $81.0 million for the second quarter of 2024, compared to income from operations of $17.9 million for the second quarter of 2023. Excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition of $2.4 million for both periods and $110.3 million in impairment charges associated with the assets related to our immersive healthcare business for the second quarter of 2024, non-GAAP income from operations¹ was $31.7 million for the second quarter of 2024 compared to non-GAAP income from operations of $20.3 million for the second quarter of 2023.

Updated Full Year 2024 Financial Outlook
The Company is updating its guidance range for 2024 total revenue to $1,180 million to $1,200 million, which is a reduction of $60 million at the midpoint from its previous guidance range of $1,230 million to $1,270 million. The $60 million change in guidance comes from 4 distinct components impacting our revenue in the second half of the year:

• $20 million reduction to our business in China due to a more challenging economic backdrop for medical devices in the near-term;
• $15 million from our European business primarily from a slight delay to the expected launch timing of FLASH and BOLT 7 CAVT products in Europe;
• $5 million in revenue from our Immersive Healthcare business, due to our strategic move; and
• Approximately $20 million change to our guidance for U.S. thrombectomy growth for full year 2024, which is now expected to be 23-25% year-over-year compared to 2023. This change aligns with our new guidance philosophy.

The Company continues to expect non-GAAP gross margin expansion in the range of 100 to 150 basis points in 2024 compared to full year 2023. The Company also continues to expect non-GAAP operating margin expansion of 100-200 basis points in 2024, with the timing of the reduction of Immersive Healthcare expenses being a primary driver of where the Company will land relative to this range.

1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

Webcast and Conference Call Information
Penumbra, Inc. will host a conference call to discuss the second quarter 2024 financial results after market close on Tuesday, July 30, 2024 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 596-4144 for domestic and international callers (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.

About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.

Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency, b) non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share ("EPS") and c) adjusted EBITDA.

Constant Currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.

Non-GAAP gross profit and non-GAAP gross margin. The adjustments to the GAAP financial measures reflect the exclusion of non-cash inventory write-down charges related to the review of our immersive healthcare asset group for impairment.

Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:

• the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives;
• the excess tax benefits associated with share-based compensation arrangements;
• non-recurring litigation related expenses; and
• non-cash long-lived asset impairment and inventory write-down charges related to the impairment of our immersive healthcare asset group.

Adjusted EBITDA. The Company's adjusted EBITDA reflects the exclusion from GAAP net (loss) income of:

• non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges;
• non-operating items such as interest income, interest expense, and (benefit from) provision for income taxes; and
• non-recurring litigation related expenses.

Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.

Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP gross profit and non-GAAP gross margin useful metrics to investors as they eliminate the impact of non-cash inventory charges related to the impairment of our immersive healthcare asset group and allow a more direct comparison of our business performance between periods. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash long-lived asset impairment and inventory write-down charges related to the impairment of our immersive healthcare asset group, the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, and expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees. Further, we consider adjusted EBITDA a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges, non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes and non-recurring litigation related expenses.

The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.

Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 22, 2024. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Penumbra, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)
		June 30, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents		$                  288,332		$                  167,486
Marketable investments		51,363		121,701
Accounts receivable, net		200,831		201,768
Inventories		373,799		388,023
Prepaid expenses and other current assets		29,470		36,424
Total current assets		943,795		915,402
Property and equipment, net		57,709		72,691
Operating lease right-of-use assets		183,316		188,756
Finance lease right-of-use assets		29,366		31,092
Intangible assets, net		6,955		71,056
Goodwill		166,050		166,270
Deferred taxes		108,852		85,158
Other non-current assets		38,518		25,880
Total assets		$               1,534,561		$               1,556,305
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable		$                    32,822		$                    27,155
Accrued liabilities		104,071		110,555
Current operating lease liabilities		11,776		11,203
Current finance lease liabilities		2,325		2,231
Total current liabilities		150,994		151,144
Non-current operating lease liabilities		192,216		197,229
Non-current finance lease liabilities		22,501		23,680
Other non-current liabilities		7,619		5,308
Total liabilities		373,330		377,361
Stockholders' equity:
Common stock		39		39
Additional paid-in capital		1,080,580		1,047,198
Accumulated other comprehensive loss		(5,048)		(3,151)
Retained earnings		85,660		134,858
Total stockholders' equity		1,161,231		1,178,944
Total liabilities and stockholders' equity		$               1,534,561		$               1,556,305

 

Penumbra, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts)
		Three Months Ended June 30,				Six Months Ended June 30,
		2024		2023		2024		2023
Revenue		$            299,403		$            261,499		$            578,058		$            502,897
Cost of revenue		136,574		94,638		234,090		184,964
Gross profit		162,829		166,861		343,968		317,933
Operating expenses:
Research and development		24,942		21,537		49,568		41,523
Sales, general and administrative		141,903		127,435		286,315		250,513
Impairment charge		76,945		—		76,945		—
Total operating expenses		243,790		148,972		412,828		292,036
(Loss) income from operations		(80,961)		17,889		(68,860)		25,897
Interest and other income, net		3,087		1,647		5,612		2,291
(Loss) income before income taxes		(77,874)		19,536		(63,248)		28,188
(Benefit from) provision for income taxes		(17,674)		576		(14,050)		666
Net (loss) income		$            (60,200)		$              18,960		$            (49,198)		$              27,522
Net (loss) income per share:
Basic		$                 (1.55)		$                   0.49		$                 (1.27)		$                   0.72
Diluted		$                 (1.55)		$                   0.48		$                 (1.27)		$                   0.70
Weighted average shares outstanding:
Basic		38,793,341		38,320,999		38,755,337		38,254,042
Diluted		38,793,341		39,201,155		38,755,337		39,151,412

 

Penumbra, Inc.
Reconciliation of GAAP Gross Profit and GAAP Gross Margin to Non-GAAP Gross Profit and Non-GAAP Gross Margin1
(unaudited)
(in thousands, except for percentages)
		Three Months Ended June 30,				Six Months Ended June 30,
		2024		2023		2024		2023
GAAP gross profit		$        162,829		$        166,861		$      343,968		$      317,933
GAAP gross profit includes the effect of the following item:
Inventory impairment charge2		33,359		—		33,359		—
Non-GAAP gross profit		$        196,188		$        166,861		$      377,327		$      317,933
GAAP gross margin		54.4 %		63.8 %		59.5 %		63.2 %
Non-GAAP gross margin		65.5 %		63.8 %		65.3 %		63.2 %

________________________

1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

2Represents a charge of $33.4 million to cost of revenue in connection with an inventory write-down to net realizable value due to the immersive healthcare asset group impairment during the three months ended June 30, 2024.

 

Penumbra, Inc.
Reconciliation of GAAP Operating Expenses and GAAP (Loss) Income from Operations to Non-GAAP Operating Expenses and Non-GAAP Income from Operations1
(unaudited)
(in thousands)
		Three Months Ended June 30,				Six Months Ended June 30,
		2024		2023		2024		2023
GAAP operating expenses		$            243,790		$            148,972		$         412,828		$         292,036
GAAP operating expenses includes the effect of the following items:
Impairment charge2		76,945		—		76,945		—
Non-recurring litigation related expenses		—		—		4,823		—
Amortization of finite lived intangible assets acquired		2,380		2,380		4,759		4,759
Non-GAAP operating expenses		$            164,465		$            146,592		$         326,301		$         287,277
GAAP (loss) income from operations		$            (80,961)		$              17,889		$          (68,860)		$           25,897
GAAP (loss) income from operations includes the effect of the following items:
Impairment charge2		110,304		—		110,304		—
Non-recurring litigation related expenses		—		—		4,823		—
Amortization of finite lived intangible assets acquired		2,380		2,380		4,759		4,759
Non-GAAP income from operations		$              31,723		$              20,269		$           51,026		$           30,656

________________________

1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024.

 

Penumbra, Inc.
Reconciliation of GAAP Net (Loss) Income and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1
(unaudited)
(in thousands, except share and per share amounts)
		Three Months Ended June 30, 2024				Three Months Ended June 30, 2023				Six Months Ended June 30, 2024				Six Months Ended June 30, 2023
		Net (loss) income		Diluted EPS		Net income		Diluted EPS		Net (loss) income		Diluted EPS		Net income		Diluted EPS
GAAP net (loss) income		$  (60,200)		$      (1.55)		$    18,960		$       0.48		$  (49,198)		$      (1.27)		$    27,522		$       0.70
GAAP net (loss) income includes the effect of the following items:
Impairment charge2		110,304		2.82		—		—		110,304		2.82		—		—
Non-recurring litigation related expenses		—		—		—		—		4,823		0.12		—		—
Amortization of finite lived intangible assets acquired		2,380		0.06		2,380		0.06		4,759		0.12		4,759		0.13
Tax effects on the non-GAAP adjustments above3		(27,157)		(0.69)		(558)		(0.01)		(28,893)		(0.73)		(1,116)		(0.03)
Excess tax benefits related to stock compensation awards		(119)		—		(3,945)		(0.10)		(406)		(0.01)		(5,385)		(0.14)
Non-GAAP net income		$    25,208		$       0.64		$    16,837		$       0.43		$    41,389		$       1.05		$    25,780		$       0.66
GAAP diluted EPS				$      (1.55)				$       0.48				$      (1.27)				$       0.70
Non-GAAP diluted EPS4				$       0.64				$       0.43				$       1.05				$       0.66
Weighted average shares outstanding used to compute:
GAAP diluted EPS		38,793,341				39,201,155				38,755,337				39,151,412
Non-GAAP diluted EPS4		39,379,142				39,201,155				39,398,553				39,151,412

________________________

1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024.

3For the three and six months ended June 30, 2024 and 2023, management used a combined federal and state tax rate of 24.10% and 23.44%, respectively, to compute the tax effect of non-GAAP adjustments.

4For the purposes of calculating Non-GAAP diluted EPS for the three and six months ended June 30, 2024, non-GAAP diluted weighted average shares outstanding of 39,379,142 and 39,398,553, respectively were used, as the Company had non-GAAP net income in the period.

 

Penumbra, Inc.
Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA and Adjusted EBITDA Margin1
(unaudited)
(in thousands, except for percentages)
		Three Months Ended June 30,				Six Months Ended June 30,
		2024		2023		2024		2023
GAAP net (loss) income		$       (60,200)		$         18,960		$       (49,198)		$         27,522
Adjustments to GAAP net (loss) income:
Depreciation and amortization expense		7,647		6,710		15,166		13,285
Interest income, net		(3,313)		(839)		(6,204)		(1,393)
(Benefit from) provision for income taxes		(17,674)		576		(14,050)		666
Stock-based compensation expense		9,560		12,823		23,129		25,589
Impairment charge2		110,304		—		110,304		—
Non-recurring litigation related expenses		—		—		4,823		—
Adjusted EBITDA		$         46,324		$         38,230		$         83,970		$         65,669
Revenue		$       299,403		$       261,499		$       578,058		$       502,897
Adjusted EBITDA		$         46,324		$         38,230		$         83,970		$         65,669
Adjusted EBITDA margin		15.5 %		14.6 %		14.5 %		13.1 %

________________________

1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024.

 

Penumbra, Inc.
Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1
(unaudited)
(in thousands, except for percentages)
		Three Months Ended June 30,				Reported Change				FX Impact		Constant Currency Change
		2024		2023		$		%		$		$		%
United States		$        218,180		$        186,772		$         31,408		16.8 %		$                —		$         31,408		16.8 %
International		81,223		74,727		6,496		8.7 %		497		6,993		9.4 %
Total		$        299,403		$        261,499		$         37,904		14.5 %		$              497		$         38,401		14.7 %
		Six Months Ended June 30,				Reported Change				FX Impact		Constant Currency Change
		2024		2023		$		%		$		$		%
United States		$        427,824		$        358,651		$         69,173		19.3 %		$                —		$         69,173		19.3 %
International		150,234		144,246		5,988		4.2 %		(141)		5,847		4.1 %
Total		$        578,058		$        502,897		$         75,161		14.9 %		$            (141)		$         75,020		14.9 %

   

Penumbra, Inc.
Reconciliation of Revenue Change by Product Categories to Constant Currency Revenue Growth1
(unaudited)
(in thousands, except for percentages)
		Three Months Ended June 30,				Reported Change				FX Impact		Constant Currency Change
		2024		2023		$		%		$		$		%
Thrombectomy		$        203,502		$        162,503		$         40,999		25.2 %		$              324		$         41,323		25.4 %
Embolization and Access		95,901		98,996		(3,095)		(3.1) %		173		(2,922)		(3.0) %
Total		$        299,403		$        261,499		$         37,904		14.5 %		$              497		$         38,401		14.7 %
		Six Months Ended June 30,				Reported Change				FX Impact		Constant Currency Change
		2024		2023		$		%		$		$		%
Thrombectomy		$        391,205		$        307,483		$         83,722		27.2 %		$                13		$         83,735		27.2 %
Embolization and Access		186,853		195,414		(8,561)		(4.4) %		(154)		(8,715)		(4.5) %
Total		$        578,058		$        502,897		$         75,161		14.9 %		$            (141)		$         75,020		14.9 %

   

Penumbra, Inc.
Reconciliation of Revenue Change by Product Categories and Geographic Regions to Constant Currency Revenue Growth1
(unaudited)
(in thousands, except for percentages)
		Three Months Ended June 30,				Reported Change				FX Impact		Constant Currency Change
		2024		2023		$		%		$		$		%
Thrombectomy
United States		$        153,728		$        123,051		$         30,677		24.9 %		$                —		$         30,677		24.9 %
International		49,774		39,452		10,322		26.2 %		324		10,646		27.0 %
Total Thrombectomy		203,502		162,503		40,999		25.2 %		324		41,323		25.4 %
Embolization and Access
United States		64,452		63,721		731		1.1 %				731		1.1 %
International		31,449		35,275		(3,826)		(10.8) %		173		(3,653)		(10.4) %
Total Embolization and Access		95,901		98,996		(3,095)		(3.1) %		173		(2,922)		(3.0) %
Total		$        299,403		$        261,499		$         37,904		14.5 %		$              497		$         38,401		14.7 %
		Six Months Ended June 30,				Reported Change				FX Impact		Constant Currency Change
		2024		2023		$		%		$		$		%
Thrombectomy
United States		$        304,013		$        234,240		$         69,773		29.8 %		$                —		$         69,773		29.8 %
International		87,192		73,243		13,949		19.0 %		13		13,962		19.1 %
Total Thrombectomy		391,205		307,483		83,722		27.2 %		13		83,735		27.2 %
Embolization and Access
United States		123,811		124,411		(600)		(0.5) %				(600)		(0.5) %
International		63,042		71,003		(7,961)		(11.2) %		(154)		(8,115)		(11.4) %
Total Embolization and Access		186,853		195,414		(8,561)		(4.4) %		(154)		(8,715)		(4.5) %
Total		$        578,058		$        502,897		$         75,161		14.9 %		$            (141)		$         75,020		14.9 %

_________________________

1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-second-quarter-2024-financial-results-302210230.html

SOURCE Penumbra, Inc.

FAQ

What was Penumbra's (PEN) revenue for Q2 2024?

Penumbra's revenue for Q2 2024 was $299.4 million, representing a 14.5% increase compared to Q2 2023.

How did Penumbra's (PEN) U.S. thrombectomy revenue perform in Q2 2024?

Penumbra's U.S. thrombectomy revenue increased by 24.9% to $153.7 million in Q2 2024 compared to the same period in 2023.

What is Penumbra's (PEN) updated revenue guidance for 2024?

Penumbra updated its 2024 revenue guidance to $1,180-$1,200 million, which is a reduction of $60 million at the midpoint from its previous guidance.

What factors led to Penumbra's (PEN) revised 2024 revenue guidance?

The revised guidance reflects challenges in China, delays in European product launches, strategic changes in Immersive Healthcare, and adjusted U.S. thrombectomy growth expectations.